CuraScript Pharmacy Signs Contract With Genentech For Distribution of
RAPTIVA(TM)
ORLANDO, Fla., Oct. 28 /PRNewswire-FirstCall/ --
CuraScript Pharmacy, Inc., the
leading national specialty pharmacy, announced today that it has been selected
by Genentech, Inc. to be a participating pharmacy in the Specialty Pharmacy
Limited Distribution Network for RAPTIVA(TM) (efalizumab), a new biologic
treatment for chronic moderate-to-severe plaque psoriasis in adults age 18 or
older.
RAPTIVA, co-developed by Genentech and XOMA Ltd. (NASDAQ:XOMA) in the United
States, was approved by the U.S. Food and Drug Administration (FDA) on October
28. RAPTIVA will be available through CuraScript Pharmacy for patients who are
prescribed this treatment by their physicians.
Dom Meffe, CuraScript President and CEO, commented, "We are pleased to again be
selected by Genentech to launch a new biologic agent. This continues to validate
CuraScript's clinical care model that brings value to patients, physicians,
healthplans, and pharmaceutical manufacturers. The CuraScript clinical team will
deploy a new PsoriasisLogic(TM) patient management program to help maximize
clinical outcomes for this exciting new product."
CuraScript is an experienced leader in the specialty pharmacy industry providing
specialty medications and support to individuals with chronic illnesses
requiring complex, high-cost treatment. CuraScript maximizes healthcare
outcomes while helping our healthplan customers manage the growing cost of
biotech medications through our industry-leading clinical programs and
commitment to patient care. The company has headquarters in Orlando, Florida and
five additional satellite facilities located throughout the nation. For
additional information on CuraScript and RAPTIVA(TM), call 888-281-5537 or visit
http://www.curascript.com/ .
DATASOURCE: CuraScript Pharmacy, Inc.
CONTACT: Valerie Thomas, +1-407-854-8015, or Nicole Visicaro,
+1-407-852-4973, both for CuraScript Pharmacy, Inc.
Web site: http://www.curascript.com/